ALK bets on well-known tablet technology to treat peanut allergy

ALK has gotten the rights to use a technology by partner Catalent to develop a peanut allergy tablet vaccine. But the Danish allergy company is far from alone on the food allergy market, where biotech firms have been testing a vast array of different technologies in recent years. Still, CEO Carsten Hellmann brushes off competition.
ALK is betting big on peanut allergy | Photo: ALK / PR
ALK is betting big on peanut allergy | Photo: ALK / PR

ALK has secured the rights to a technology it will use to develop a tablet against peanut allergy, which will be one of the most important growth drivers in the years post-2025, according to the Danish allergy company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading